"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h

#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.

Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews

#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow

Do patients with #SpA have a different phenotype if they have "root joint disease"? Find out at the #EULAR2021 Poster Tour #POS0239 or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9

• Root Joint Involvement in Spondyloarthritis: A Post-hoc Analysis from the Inter…

@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?

Don’t forget to use imaging that you already have! CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis ⭐️60/301 had sacroilitis on CT ⭐️11/60 had AxSpA ⭐️3/60 previously undiagnosed axSpA Abs#POS0035 #EULAR2021 @RheumNow

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR